Advertisement

Tumor Biology

, Volume 34, Issue 2, pp 1045–1052 | Cite as

Association between microsomal epoxide hydrolase 1 T113C polymorphism and susceptibility to lung cancer

  • Siwen Wang
  • Jie Zhu
  • Ruxin Zhang
  • Siyang Wang
  • Zongheng Gu
Research Article

Abstract

Previous case–control studies assessing the association between microsomal epoxide hydrolase 1 (EPHX1) T113C and susceptibility to lung cancer reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. PubMed and Embase databases were searched for all eligible studies. The strength of the association between EPHX1 T113C polymorphism and lung cancer risk was estimated by the pooled odds ratios (ORs) with its 95 % confidence interval. Twenty-four individual case–control studies involving a total of 4,970 lung cancer cases and 8,917 controls were finally included into the meta-analysis. When all 24 studies were included into the meta-analysis, the pooled results suggested that there was no association between EPHX1 T113C polymorphism and lung cancer risk under all four comparison models, and all P values for the pooled ORs were more than 0.05. In the subgroup analysis of Caucasians, the pooled results suggested that EPHX1 T113C polymorphism was associated with decreased risk of lung cancer under all four comparison models, and all P values for the pooled ORs were less than 0.05. However, in the subgroup analysis of Asians, the pooled results suggested that EPHX1 T113C polymorphism was associated with increased risk of lung cancer under three comparison models, and all P values for the pooled ORs were less than 0.05. There was no risk of publication bias. This current meta-analysis suggests that EPHX1 T113C polymorphism is associated with lung cancer risk, and there is an obvious race-specific effect in the association.

Keywords

Lung cancer EPHX1 T113C Meta-analysis Polymorphism 

Notes

Conflicts of interest

The authors declared that they have no competing interests.

References

  1. 1.
    Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359:1367–80.PubMedCrossRefGoogle Scholar
  3. 3.
    Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7:778–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9:377–84.PubMedCrossRefGoogle Scholar
  5. 5.
    Chen X, Liang L, Hu X, Chen Y. Glutathione S-transferase P1 gene Ile105Val polymorphism might be associated with lung cancer risk in the Chinese Han population. Tumour Biol. 2012;33:1973–81.PubMedCrossRefGoogle Scholar
  6. 6.
    de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, Almeida MI, Cunha J, Oliveira P, Hespanhol V, Reis RM. Association between EGF +61 genetic polymorphisms and non-small cell lung cancer increased risk in a portuguese population: a case–control study. Tumour Biol. 2012;33:1341–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Liu J, Liao Q, Zhang Y, Sun S, Zhong C, Liu X. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33:1467–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol. 2009;83:297–318.PubMedCrossRefGoogle Scholar
  9. 9.
    Arand M, Cronin A, Oesch F, Mowbray SL, Jones TA. The telltale structures of epoxide hydrolases. Drug Metab Rev. 2003;35:365–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a huge review. Epidemiology. 2006;17:89–99.PubMedCrossRefGoogle Scholar
  11. 11.
    Hu G, Shi Z, Hu J, Zou G, Peng G, Ran P. Association between polymorphisms of microsomal epoxide hydrolase and copd: results from meta-analyses. Respirology. 2008;13:837–50.PubMedCrossRefGoogle Scholar
  12. 12.
    Tilak AR, Kumar S, Jain M, Pant MC, Das BC, Guleria R, Mittal B, Mathur N, Kumar A. Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility. Cancer Invest. 2011;29:411–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, Zomawia E, Verma Y, Kapur S, Saxena S. Multiple analytical approaches reveal distinct gene–environment interactions in smokers and non smokers in lung cancer. PLoS One. 2011;6:e29431.PubMedCrossRefGoogle Scholar
  14. 14.
    Timofeeva M, Kropp S, Sauter W, Beckmann L, Rosenberger A, Illig T, Jager B, Mittelstrass K, Dienemann H, Bartsch H, Bickeboller H, Chang-Claude J, Risch A, Wichmann HE. Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int J Cancer. 2010;127:1547–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wolke G, Meese E, Sybrecht G, Kronenberg F, Cebulla M, Degen M, Drings P, Groschel A, Konietzko N, Kreymborg KG, Haussinger K, Hoffken G, Jilge B, Ko YD, Morr H, Schmidt C, Schmidt EW, Tauscher D, Bickeboller H, Wichmann HE. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer. 2008;8:60.PubMedCrossRefGoogle Scholar
  16. 16.
    Voho A, Metsola K, Anttila S, Impivaara O, Jarvisalo J, Vainio H, Husgafvel-Pursiainen K, Hirvonen A. EPHX1 gene polymorphisms and individual susceptibility to lung cancer. Cancer Lett. 2006;237:102–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Liang GY, Pu YP. Yin LH: [studies of the genes related to lung cancer susceptibility in Nanjing Han population, China]. Yi Chuan. 2004;26:584–8.PubMedGoogle Scholar
  18. 18.
    Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G, Hollaus P, Mohn-Staudner A, Armbruster C, Madersbacher S, Schatzl G, Trieb K, Vutuc C, Micksche M. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer. 2003;89:702–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing. China Lung Cancer. 2001;33:133–41.CrossRefGoogle Scholar
  21. 21.
    Wu X, Gwyn K, Amos CI, Makan N, Hong WK, Spitz MR. The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African–Americans and Mexican–Americans. Carcinogenesis. 2001;22:923–8.PubMedCrossRefGoogle Scholar
  22. 22.
    To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, Corbella J. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett. 2001;173:155–62.PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, Yamakido M. Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med. 2000;5:49–53.PubMedGoogle Scholar
  24. 24.
    London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African–Americans and Caucasians in Los Angeles County. Lung Cancer. 2000;28:147–55.PubMedCrossRefGoogle Scholar
  25. 25.
    Persson I, Johansson I, Lou YC, Yue QY, Duan LS, Bertilsson L, Ingelman-Sundberg M. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer. 1999;81:325–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 1998;58:5291–3.PubMedGoogle Scholar
  27. 27.
    Zhou W, Thurston SW, Liu G, Xu LL, Miller DP, Wain JC, Lynch TJ, Su L, Christiani DC. The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:461–6.PubMedGoogle Scholar
  28. 28.
    Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gaborieau V, Gioia-Patricola L, Bellini I, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis. 2007;28:1287–93.PubMedCrossRefGoogle Scholar
  29. 29.
    Park JY, Chen L, Elahi A, Lazarus P, Tockman MS. Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk. Eur J Cancer Prev. 2005;14:223–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Smith CA, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet. 1997;350:630–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Graziano C, Comin CE, Crisci C, Novelli L, Politi L, Messerini L, Andreani M, Porfirio B. Functional polymorphisms of the microsomal epoxide hydrolase gene: a reappraisal on a early-onset lung cancer patients series. Lung Cancer. 2009;63:187–93.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhao H, Spitz MR, Gwyn KM, Wu X. Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog. 2002;33:99–104.PubMedCrossRefGoogle Scholar
  33. 33.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  35. 35.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  36. 36.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  37. 37.
    Sun XW, Ma YY. Wang B: [The interaction between microsomal epoxide hydrolase polymorphisms and indoor pollution in non small cell lung cancer]. Zhonghua Yu Fang Yi Xue Za Zhi. 2007;41(Suppl):30–4.PubMedGoogle Scholar
  38. 38.
    Erkisi Z, Yaylim-Eraltan I, Turna A, Gormus U, Camlica H, Isbir T. Polymorphisms in the microsomal epoxide hydrolase gene: role in lung cancer susceptibility and prognosis. Tumori. 2010;96:756–63.PubMedGoogle Scholar
  39. 39.
    Wang N, Wu Y. Zhou X: [Association between genetic polymorphism of metabolizing enzymes and DNA repairing enzymes and the susceptibility of lung cancer in henan population]. Wei Sheng Yan Jiu. 2012;41:251–6.PubMedGoogle Scholar
  40. 40.
    Liu H, Li HY, Chen HJ, Huang YJ, Zhang S, Wang J: EPHX1 A139G polymorphism and lung cancer risk: a meta-analysis. Tumour Biol 2012 [Ahead of print].Google Scholar
  41. 41.
    Xiao XY, Wang XD, Zang DY. MMP1-1607 1 G/2G polymorphism and lung cancer risk: a meta-analysis. Tumour Biol. 2012;33:2385–92.PubMedCrossRefGoogle Scholar
  42. 42.
    Zhao ZQ, Guan QK, Yang FY, Zhao P, Zhou B, Chen ZJ. System review and meta-analysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk. Tumour Biol. 2012;33:523–35.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Siwen Wang
    • 1
  • Jie Zhu
    • 1
  • Ruxin Zhang
    • 1
  • Siyang Wang
    • 2
  • Zongheng Gu
    • 1
  1. 1.Department of Emergencythe Fourth Affiliated Hospital of China Medical UniversityShenyang CityPeople’s Republic of China
  2. 2.Department of Infectious Diseasesthe First Affiliated Hospital, China Medical UniversityShenyangChina

Personalised recommendations